Heart Failure and Edema Costs in Patiromer and Sodium Zirconium Cyclosilicate Users

帕替罗默和环硅酸锆钠使用者的心力衰竭和水肿费用

阅读:1

Abstract

KEY POINTS: Prior research suggests differences in rates of heart failure hospitalization or serious emergency department visits between patients on patiromer versus sodium zirconium cyclosilicate. Total costs of heart failure–related hospitalizations and emergency department visits may be lower in patients on patiromer compared with sodium zirconium cyclosilicate. BACKGROUND: Previous work suggested differences between patients taking patiromer or sodium zirconium cyclosilicate (SZC) in real-world risk of heart failure (HF) hospitalizations and edema hospitalizations or emergency department (ED) visits (edema events). We further investigated these differences to assess economic importance. Retrospective study using published event rates and mean costs derived from Optum's deidentified Clinformatics Data Mart Database. METHODS: We designed a model to estimate adjusted economic offsets that combined respective patiromer and SZC HF hospitalization (25.1 and 35.8; difference 10.7 [95% confidence interval (CI)(2), 2.6 to 18.8]) and edema event (3.4 and 7.1; difference 3.6 [95% CI, 1.7 to 7.1]) rates/100 person-years from the original published work with costs from our parallel data extract spanning 2019–2021, adjusted to 2021 US dollars. RESULTS: In a base case of mean HF hospitalization, edema event, and 30-count potassium-binder prescription costs from our data extract, the estimated mean savings with patiromer was $1428 per person per year (95% CI, −$1508 to $4652). Respective costs per person per year for patiromer versus SZC were $8526 versus $12,622 (difference $4096 [95% CI, $116 to $7320]) for HF hospitalization and edema events, and $10,649 versus $7981 (difference −$2668) for potassium binders, totaling $19,175 for patiromer versus $20,603 for SZC. CONCLUSIONS: With differing drug costs, hospitalization and ED costs offset this difference when event rates were numerically small. Model outcomes were driven by HF hospitalization cost and least influenced by edema ED visit cost. A limitation was that the Clinformatics Data Mart data extract may differ from the original work.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。